Screening

MDLink to Launch Coronavirus Screening Tool and Intends to Provide Rapid Test Kits to Tourist

Wednesday, June 3, 2020 - 1:30pm

MDLink intends to supply FDA approved COVID-19 rapid test kits to tourists.

Key Points: 
  • MDLink intends to supply FDA approved COVID-19 rapid test kits to tourists.
  • Screening tool will also have access to the rapid test home kits if they are screened into a high vulnerability index category by the MDLink Chatbot.
  • MDLink is proud to announce it will be rolling out an artificial intelligence novel coronavirus screening online platform in collaboration with the IDB Lab, for members of the public.
  • Its a screening tool that checks symptoms and directs the user to the right medical facility or to stay home, MDLink Chief Executive Officer, Dr. Che' Bowen, said.

Global Breast Cancer Screening Market Outlook, 2020-2026: A $51.8 Billion Opportunity Assessment

Wednesday, June 3, 2020 - 11:45am

In the year 2020, the global breast cancer screening population, as well as the market, will decline.

Key Points: 
  • In the year 2020, the global breast cancer screening population, as well as the market, will decline.
  • Growing breast cancer incidences & mortality in the low and middle-income countries, these countries need to develop an effective breast cancer screening program strategy that will address the earlier deduction of incidence of breast cancer for women.
  • Some of the major breast cancer screening technologies which help to find breast cancer after diagnosis are as follows.
  • Countries - Total 23 Countries Market & Population for Breast Cancer Screening, Mammography Screening, MRI Screening & Ultrasound Screening has been studied in the report
    The study includes a comprehensive Breast cancer overview of Canada, France, Italy, Spain, Switzerland, Netherlands, Norway, India, Australia, Japan, Korea, Singapore, Thailand, Malaysia, Brazil, New Zealand, South Africa, United Arab Emirates and Saudi Arabia Breast Cancer, Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population and Market.

OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

Tuesday, June 2, 2020 - 1:35pm

OrphoMed paused screening of new patients on March 27, 2020, in response to the COVID-19 pandemic.

Key Points: 
  • OrphoMed paused screening of new patients on March 27, 2020, in response to the COVID-19 pandemic.
  • Study screening will resume on a clinical investigational site-by-site basis as authorities lift shelter-in-place directives.
  • During the study screening hold, we worked diligently to continue the study as planned and to treat and evaluate patients already participating in the study safely and effectively, said Dr. Steinberg.
  • We look forward to continued support from our investigators and study staff to efficiently complete the planned enrollment in this study.

Axcelead Boosts Integrated Drug Discovery Services for Biopharma with Genedata Screener

Tuesday, June 2, 2020 - 8:00am

TOKYO, June 2, 2020 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that leading Japanese solution provider in the drug discovery space Axcelead Drug Discovery Partners, a driver of innovation in research and Japan's first provider of integrated drug discovery services, has expanded its license for Genedata Screener, the market-leading solution for efficient and automated screening data analysis.

Key Points: 
  • TOKYO, June 2, 2020 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that leading Japanese solution provider in the drug discovery space Axcelead Drug Discovery Partners, a driver of innovation in research and Japan's first provider of integrated drug discovery services, has expanded its license for Genedata Screener, the market-leading solution for efficient and automated screening data analysis.
  • Axcelead is adopting Genedata Screener to ramp up capacity for its R&D programs, and for routinely offering specialized services on modern screening technologies for thermal shift and ion channel screening.
  • "With Genedata Screener we can deliver what biopharma companies are searching for in a partner for drug discovery: fast completion of projects and the highest data quality," said Junji Matsui, Head of Discovery Science at Axcelead.
  • We are proud that Axcelead has selected our Genedata Biopharma Platform for its strategy to deliver the highest quality services to its rapidly increasing customer base," commented Othmar Pfannes, Ph.D., CEO of Genedata.

CellMax Life Shares Additional Data from its U.S. Study for FirstSight Blood Test to Detect Colorectal Precancerous Adenomas and Cancer

Monday, June 1, 2020 - 2:00pm

With a blood test, FirstSight testing has the potential to identify those who may benefit from closer surveillance, reducing colorectal cancer (CRC) incidence.

Key Points: 
  • With a blood test, FirstSight testing has the potential to identify those who may benefit from closer surveillance, reducing colorectal cancer (CRC) incidence.
  • CellMax Life continues to enroll patients at the Veterans Affairs Hospital and has now opened the study to additional sites across the United States to further validate the FirstSight blood test.
  • CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancer and cancer cells, and genomic markers in a single blood sample.
  • CellMax Life is headquartered in Sunnyvale, California, and has a CLIA certified and CAP accredited laboratory at this location.

Free Online Infrared (IR) Temperature Measurement Training for Fever Detection Now Live From American Academy of Thermology (AAT)

Monday, June 1, 2020 - 2:00pm

To help, the AAT has issued and published new, science-based temperature measurement fever screening training programs and recommendations (available now at http://courses.aathermology.org ).

Key Points: 
  • To help, the AAT has issued and published new, science-based temperature measurement fever screening training programs and recommendations (available now at http://courses.aathermology.org ).
  • Our free, online training courses and white paper on IR temperature measurement and fever screening offer individuals, businesses, and agencies a reliable educational format to help assure that IR fever screening is being done right.
  • In the absence of proper training it is very common for someone who uses infrared thermometers or cameras to perform fever screening to do it wrong.
  • IR temperature measurement is non-contact, and better still, with medical grade devices it can be obtained while still practicing social distancing.

Creatv Announces Positive Results for the LifeTracDx Blood Test in the Detection of Early Stage Cancer in Multiple Solid Tumors

Friday, May 29, 2020 - 5:35pm

Creatv MicroTech , a privately-held biotechnology company has pioneered a blood test for the universal screening of early stage cancer.

Key Points: 
  • Creatv MicroTech , a privately-held biotechnology company has pioneered a blood test for the universal screening of early stage cancer.
  • This represents a significant step towards pan cancer screening by a routine blood draw with high sensitivity and specificity.
  • Creatvs poster, Circulating Stromal Cells as a Blood Based Biomarker for Screening Invasive Solid Tumors, Abstract ID: 3535, highlights the performance of the LifeTracDxTM blood test.
  • Creatv is a privately-held cancer screening and diagnostic company founded in 2000, featuring expertise in both biodetection and microfabrication.

Around the Clock Healthcare Services (ATC) to Offer Turn-Key Onsite COVID-19 Testing Services to All Businesses

Friday, May 29, 2020 - 1:31pm

Today, rising unemployment, repairing the economy, re-opening business, and bringing back workforces safely, including through the utilizations of various testing options, are key topic's in today's news cycle.

Key Points: 
  • Today, rising unemployment, repairing the economy, re-opening business, and bringing back workforces safely, including through the utilizations of various testing options, are key topic's in today's news cycle.
  • By partnering with ATC, businesses will be able to ensure a safe and healthy work environment for their employees without incurring the unnecessary burden of coordinating testing.
  • ATC has taken the steps to invest in those resources that are necessary to provide this comprehensive and unique quality testing solution.
  • Screening: ATC is providing comprehensive screening services to ensure that employees are safe to come into the work place on a daily basis.

Global Security Screening Market 2020-2025: Assessment of Impact of Covid-19 on the Security Screening Market

Thursday, May 28, 2020 - 7:00pm

Security screening enables the assurance from threat against unethical and unlawful practices and protecting financials and humans.

Key Points: 
  • Security screening enables the assurance from threat against unethical and unlawful practices and protecting financials and humans.
  • Security screening using various technologies such as X-ray scanners, biometric matching, and metal detectors, that are getting very popular at the security checkpoints for expediting the process.
  • The application of security screening has witnessed a positive shift toward a more technologically-advanced approach with the rising demand for enhanced security across the world.
  • TSA also mentioned that, these automated security screening reduced a security screening time by over 30%.

Netsmart Launches COVID-19 Mobile Screening Solution

Thursday, May 28, 2020 - 7:00pm

Netsmart launches a COVID-19 Mobile Screening Solution to help organizations safely re-open as stay at home orders are lifted around the country.

Key Points: 
  • Netsmart launches a COVID-19 Mobile Screening Solution to help organizations safely re-open as stay at home orders are lifted around the country.
  • The Netsmart COVID-19 Mobile Screening Solution supports all healthcare communities and can be used as a safety measure for staff, clients and visitors.
  • The COVID-19 Mobile Screening Solution records the results and prior testing in the Netsmart CarePathways analytics platform for visualization, trending, and hot spot mapping.
  • Netsmart is offering the COVID-19 Mobile Screening Solution at no cost for 90 days, then a nominal recurring fee will ensue after the 90 day period.